DE602006008187D1 - 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin-derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten - Google Patents

4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin-derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten

Info

Publication number
DE602006008187D1
DE602006008187D1 DE602006008187T DE602006008187T DE602006008187D1 DE 602006008187 D1 DE602006008187 D1 DE 602006008187D1 DE 602006008187 T DE602006008187 T DE 602006008187T DE 602006008187 T DE602006008187 T DE 602006008187T DE 602006008187 D1 DE602006008187 D1 DE 602006008187D1
Authority
DE
Germany
Prior art keywords
ethethiophen
pyrimidin
benzo
cancer
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006008187T
Other languages
German (de)
English (en)
Inventor
Karl Robert Dahnke
Ho-Shen Lin
Chuan Shih
Q May Wang
Bo Zhang
Michael Enrico Richett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of DE602006008187D1 publication Critical patent/DE602006008187D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE602006008187T 2005-11-18 2006-11-15 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin-derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten Active DE602006008187D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (1)

Publication Number Publication Date
DE602006008187D1 true DE602006008187D1 (de) 2009-09-10

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006008187T Active DE602006008187D1 (de) 2005-11-18 2006-11-15 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin-derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten

Country Status (27)

Country Link
US (1) US7547691B2 (https=)
EP (1) EP1989200B1 (https=)
JP (1) JP2009516697A (https=)
KR (1) KR100990771B1 (https=)
CN (1) CN101309918B (https=)
AR (1) AR057911A1 (https=)
AT (1) ATE437873T1 (https=)
AU (1) AU2006337626B2 (https=)
BR (1) BRPI0618245A2 (https=)
CA (1) CA2629336A1 (https=)
CR (1) CR9947A (https=)
DE (1) DE602006008187D1 (https=)
DK (1) DK1989200T3 (https=)
EA (1) EA014426B1 (https=)
EC (1) ECSP088456A (https=)
ES (1) ES2329085T3 (https=)
IL (1) IL190489A0 (https=)
MA (1) MA30053B1 (https=)
NO (1) NO20082594L (https=)
PE (1) PE20070833A1 (https=)
PL (1) PL1989200T3 (https=)
PT (1) PT1989200E (https=)
SI (1) SI1989200T1 (https=)
TN (1) TNSN08227A1 (https=)
TW (1) TW200800201A (https=)
WO (1) WO2007092095A2 (https=)
ZA (1) ZA200803940B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2007752T3 (pl) 2006-03-31 2011-02-28 Janssen Pharmaceutica Nv Benzoimidazol-2-ilopirymidyny i pirazyny jako modulatory receptora histaminowego H4
AU2007275221A1 (en) * 2006-07-20 2008-01-24 Allen J. Borchardt Benzothiophene inhibitors of RHO kinase
DK2125794T3 (da) * 2006-12-21 2011-01-24 Lilly Co Eli Imidazolidinonylaminopyrimidin-forbindelser til behandling af cancer
ES2349169T3 (es) * 2006-12-21 2010-12-28 ELI LILLY & COMPANY Compuestos de imidazolidinonil aminopirimidina para el tratamiento del cáncer.
CN101679396B (zh) 2007-05-16 2012-06-06 伊莱利利公司 三唑基氨基嘧啶化合物
US8063035B2 (en) 2007-05-16 2011-11-22 Eli Lilly And Company Triazolyl aminopyrimidine compounds
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
TWI498326B (zh) 2008-06-30 2015-09-01 Janssen Pharmaceutica Nv 用於製備經取代之嘧啶衍生物之化合物
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
MX2012001974A (es) 2009-08-19 2012-04-11 Ambit Biosciences Corp Compuestos de biarilo y metodos de uso de los mismos.
CN102858764B (zh) 2010-04-27 2014-08-20 和记黄埔医药（上海）有限公司 嘧啶基吲哚化合物
WO2013058824A1 (en) 2011-04-07 2013-04-25 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
WO2013119895A1 (en) * 2012-02-08 2013-08-15 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
PT3494119T (pt) 2016-07-29 2024-12-10 Pgi Drug Discovery Llc Compostos e composições e seus usos
MA45795A (fr) 2016-07-29 2019-06-05 Sunovion Pharmaceuticals Inc Composés et compositions, et utilisations associées
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140513A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
US11136308B2 (en) 2017-01-26 2021-10-05 Araxes Pharma Llc Substituted quinazoline and quinazolinone compounds and methods of use thereof
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US10745385B2 (en) 2017-05-25 2020-08-18 Araxes Pharma Llc Covalent inhibitors of KRAS
CA3070993C (en) 2017-08-02 2025-05-20 Sunovion Pharmaceuticals Inc. ISOCHROMANE COMPOUNDS AND THEIR USES
MX2021000887A (es) 2018-08-01 2021-03-31 Araxes Pharma Llc Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
EP3938045A1 (en) 2019-03-14 2022-01-19 Sunovion Pharmaceuticals Inc. Salts of a isochromanyl compound and crystalline forms, processes for preparing, therapeutic uses, and pharmaceutical compositions thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3752589A (en) * 1988-05-16 1989-12-12 Georgia State University Research Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
EP1831207B1 (en) 2004-12-17 2012-11-14 Amgen Inc. Aminopyrimidine compounds as plk inhibitors

Also Published As

Publication number Publication date
AU2006337626A8 (en) 2008-06-19
ECSP088456A (es) 2008-06-30
KR100990771B1 (ko) 2010-10-29
US20080306082A1 (en) 2008-12-11
WO2007092095A3 (en) 2007-11-08
TNSN08227A1 (en) 2009-10-30
CR9947A (es) 2008-11-28
WO2007092095A2 (en) 2007-08-16
CN101309918A (zh) 2008-11-19
KR20080059451A (ko) 2008-06-27
BRPI0618245A2 (pt) 2011-08-23
JP2009516697A (ja) 2009-04-23
IL190489A0 (en) 2008-11-03
EA014426B1 (ru) 2010-12-30
US7547691B2 (en) 2009-06-16
TW200800201A (en) 2008-01-01
NO20082594L (no) 2008-06-10
AR057911A1 (es) 2007-12-26
ES2329085T3 (es) 2009-11-20
PL1989200T3 (pl) 2009-12-31
PT1989200E (pt) 2009-10-12
AU2006337626A1 (en) 2007-08-16
CA2629336A1 (en) 2007-08-16
AU2006337626B2 (en) 2012-03-22
CN101309918B (zh) 2010-12-29
PE20070833A1 (es) 2007-08-27
EP1989200B1 (en) 2009-07-29
EA200801362A1 (ru) 2009-02-27
ATE437873T1 (de) 2009-08-15
ZA200803940B (en) 2009-09-30
SI1989200T1 (sl) 2009-12-31
EP1989200A2 (en) 2008-11-12
DK1989200T3 (da) 2009-11-09
MA30053B1 (fr) 2008-12-01

Similar Documents

Publication Publication Date Title
DE602006008187D1 (de) 4-(benzoäbüthiophen-2-yl)-pyrimidin-2-ylü-amin-derivate als ikk-beta-hemmer für die behandlung von krebs und entzündungskrankheiten
ATE381558T1 (de) Substituierte pyridinyl und pyrimidinyl derivate als modulatoren eines metabolismus für die behandlung von damit inzusammenhangstehenden krankheiten
EP1898930A4 (en) Treatment of inflammatory conditions
ATE415397T1 (de) Substituierte aryl- und heteroarylderivate als modulatoren des stoffwechsels und für die prophylaxe und behandlung von damit in zusammenhang stehenden erkrankungen
ATE432273T1 (de) 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n- arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen
CY2018028I2 (el) Βενζοθειοφαινια υποκατεστημενα με πιπεραζινη για την αγωγη διανοητικων διαταραχων
ATE505472T1 (de) Pyridinderivate und ihre verwendung bei der behandlung psychotischer erkrankungen
ATE478864T1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
ATE390422T1 (de) Quinazolin-derivate für die behandling von krebs
ATE523508T1 (de) Für die behandlung von zellproliferativen erkrankungen geeignete pyridin- und pyrazinderivate
DE602006018057D1 (de) Substituierte chinolone und verwendungsverfahren
NO20081539L (no) Middel for behandling av betennelsestarmsykdom
ATE538114T1 (de) 4-(pyridin-4-yl)-1h-ä1,3,5ütriazin-2-onderivate als gsk3-beta-inhibitoren zur behandlung neurodegenerativer krankheiten
DE602005005810D1 (de) Verwendung von substituierten chinolin-derivaten zur behandlung von arzneimittelresistenten mycobakteriellen erkrankungen
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
ATE424386T1 (de) Pyridin-verbindungen für die behandlung von prostaglandin-vermittelten krankheiten
ATE437861T1 (de) 2-(amino-substituierte)-4-arylpyramidine und verwandte verbindungen, die sich für die behandlung von entzündlichen krankheiten eignen
ATE502944T1 (de) 2-amino-5,7-dihydro-6h-pyrroloä3,4- düpyrimidinderivate als hsp-90-inhibitoren zur behandlung von krebs
ATE465150T1 (de) Für die behandlung von durch den gpr38-rezeptor vermittelten krankheiten geeignete piperazinylderivate
DE602006010449D1 (de) Behandlung von geflügel zwecks reduzierung der futon ascites
EP1863520A4 (en) USE OF INTERLEUKIN 17E FOR THE TREATMENT OF CANCER
DE602006021192D1 (de) Visnadin zur Behandlung von Kopfhautjucken
ATE443991T1 (de) Verwendung von phenylsemicarbazonen für die saatgutbeizung
ATE542804T1 (de) 5-phenyl-pentansäurederivate als matrixmetalloproteinase-inhibitoren zur behandlung von asthma und anderen erkrankungen
ITRM20050179A1 (it) Composizione impiegabile per il trattamento delle patologie paradontali.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN